EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Clinical trials for EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) trials appear
Sign up with your email to follow new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for advanced cancers: IDE161 trial begins
Disease control Recruiting nowThis study tests a new drug called IDE161, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The goal is to find a safe dose and see if it can shrink tumors. About 216 adults with tumors that have sp…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated May 26, 2026 11:12 UTC
-
New hope for tough lung cancer: phase 3 trial pits targeted drug against standard care
Disease control Recruiting nowThis study tests whether the drug sacituzumab govitecan helps people with advanced small cell lung cancer live longer compared to standard treatments. About 695 adults whose cancer worsened after one round of chemotherapy will be randomly assigned to receive either the study drug…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated May 26, 2026 11:12 UTC
-
New hope for aggressive lung cancer: Triple-Drug combo trial launches
Disease control Recruiting nowThis study tests whether adding extra drugs to a standard chemo-and-immunotherapy regimen can better control extensive-stage small cell lung cancer. About 180 adults who have not had prior treatment will be randomly assigned to one of three groups, each receiving the drug ivonesc…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated May 26, 2026 11:07 UTC
-
New drug cocktail aims to stall aggressive lung cancer
Disease control Recruiting nowThis study tests whether combining two FDA-approved drugs—sacituzumab govitecan and an immunotherapy (atezolizumab or durvalumab)—can control tumor growth in adults with extensive-stage small cell lung cancer. Participants receive treatment every 21 days for up to 2 years, with r…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Bindu R Potugari • Aim: Disease control
Last updated May 26, 2026 11:04 UTC
-
New combo therapy aims to slow aggressive lung cancer
Disease control Recruiting nowThis study tests whether adding the drug tislelizumab to standard chemotherapy and radiation can help people with extensive small cell lung cancer live longer without the disease getting worse. About 56 adults who have not had prior treatment for this advanced lung cancer will re…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated May 26, 2026 11:03 UTC
-
Lung cancer drug shows promise for patients with specific gene
Disease control Recruiting nowThis study tests a drug called teniposide in people with a hard-to-treat type of lung cancer that has spread and has not responded to standard treatments. The cancer must have a specific gene change (c-Myc-driven). The goal is to see if the drug can shrink tumors and control the …
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated May 26, 2026 11:03 UTC
-
New drug combo aims to extend life in tough lung cancer
Disease control Recruiting nowThis study tests whether adding a new drug called obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults will be randomly assigned to get either the new combo or standard treatment alone. The goal is t…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 26, 2026 11:00 UTC
-
New hope for tough lung cancer: triple therapy trial launches
Disease control Recruiting nowThis early-phase study is for people with extensive-stage small cell lung cancer whose disease persisted, returned, or got worse after standard chemotherapy. The trial combines an experimental drug (iadademstat) with targeted radiation and an immunotherapy (atezolizumab) to see i…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE1 • Sponsor: Yale University • Aim: Disease control
Last updated May 18, 2026 11:58 UTC
-
New hope for advanced lung cancer: drug combo plus radiation shows promise
Disease control Recruiting nowThis study tests a new treatment for people with extensive stage small cell lung cancer, a fast-growing cancer that has spread. It combines the drug tislelizumab with chemotherapy, followed by chest radiation, then maintenance therapy. The goal is to see how long the cancer stays…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated May 15, 2026 11:53 UTC